Pharmacologic treatments for covid-19 patients

We are searching the literature every day and collecting data for each RCT of COVID-19 treatment identified.

Below you can access all the treatment comparisons where data are available as well as a table with the general characteristics of each trial. For each treatment comparison, you can access the forest plots for all the outcomes of interest available as well as the Summary of Findings (SoF) table.

We are updating the evidence synthesis every Friday, we are prioritizing the updates for comparisons with results for at least two studies.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison type then a Treatment Comparison:

    Anti-virals (30 comparisons)

    Other antimicrobials (antibiotics, antimalarials, antiparasitics) (9 comparisons)

    NSAIDs and Anti-inflammatories (2 comparisons)

    Kinase inhibitor (2 comparisons)

    Corticosteroids (2 comparisons)

    Monoclonal antibodies (5 comparisons)

    Immunosupressant (1 comparisons)

    Convalescent plasma (2 comparisons)

    Antithrombotic (antiplatelet, anticoagulant, thrombolytic drug) (1 comparisons)

    Other Advanced therapy medicinal products (ATMP) (2 comparisons)

    Others (14 comparisons)

Reboot the table and see all comparisons

Network diagrams

Networks

The nodes represent the interventions being compared in the available RCTs. Two interventions are connected with a line whenever there is at least one RCT comparing them directly. The size of the nodes is proportional to the total number of participants randomised in each intervention and the thickness of the line is proportional to the precision (i.e. the inverse of the variance) of the relative effect for the respective direct comparison. The color of the lines represents the overall risk of bias of the direct comparisons for the outcome that corresponds to each network diagram. When two or more RCTs compare the same pair of interventions, then the risk of bias of that comparison is calculated as the inverse variance weighted average of the study-specific overall risk of bias judgements.

Description of primary studies

In this table, we report the main characteristics of the RCTs identified.

The link in the column Overall risk of bias will give you access to a complete description of the assessment of each risk of bias domain with supports for judgement. The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column Full description will give you access to the general characteristics of the study.

The components included in the standard of care vary among the included studies. For example, the standard of care may include antiviral treatments in some studies, but not in others. We are in the process of contacting the study authors to obtain more information.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Full description
Treatment 1 Treatment 2
IRCT20200328046886N1
Abbaspour Kasgari H, J Antimicrob Chemother , 2020
Full text
Commentary
Public/non profit Sofosbuvir/daclatasvir + Ribavirin Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Iran. N=48
Some concerns
Details

Full description

CTRI/2020/04/024775
Agarwal A, medRxiv, 2020
Full text
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (mild to severe) admitted to 39 centers in India. N=464
High
Details

Full description

new
NCT04573153
Altay O, medRxiv, 2020
Full text
Commentary
Private Combined metabolic cofactor supplementation Placebo RCT Patients with confirmed COVID-19 (mild) treated ata single center in Turkey N=100
Some concerns
Details

Full description

NCT02735707
Angus DC, JAMA, 2020
Full text
Commentary
Public/non profit Hydrocortisone Standard care RCT Patients with COVID-19 (severe-critical) admitted to 121 centers in 8 countries N=251
Some concerns
Details

Full description

IRCT20200317046797N4
Ansarin K, Bioimpacts, 2020
Full text
Commentary
Public/non profit Bromhexine Standard care RCT Patients with COVID-19 (unclear severity) at a single center in Iran N=78
Some concerns
Details

Full description

NCT04345523
Avendaño-Solà C, medRxiv, 2020
Full text
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 14 centers in Spain N=81
Some concerns
Details

Full description

NCT04375098
Balcells M, medRxiv, 2020
Full text
Commentary
and Commentary
Public/non profit Early Convalescent plasma Late Convalescent plasma RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single centre in Chile. N=58
Low
Details

Full description

NCT04280705
Beigel JH, N Engl J Med, 2020
Full text
Commentary
Public/non profit Remdesivir Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to 60 centers in 10 countries. N=1062
Low
Details

Full description

NCT04323527
Borba MGS, Jama Netw Open, 2020
Full text
Commentary
Public/non profit Chloroquine - 600mg Chloroquine - 450mg RCT Patients with severe and critical respiratory syndrome secondary to SARS-CoV-2 infection treated in a single center in Brazil. N=81
Some concerns
Details

Full description

Forest plots
ChiCTR2000029308
Cao B, N Engl J Med, 2020
Full text
Commentary
and Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with confirmed COVID-19 (severe) admitted to a single center in China. N=199
Some concerns
Details

Full description

ChiCTR-OPN-200002958
Cao Y, J Allergy Clin Immun, 2020
Full text
Commentary
Public/non profit Ruxolitinib Vitamin C RCT Patients with COVID-19 (severe) admitted to 3 centers in China. N=43
High
Details

Full description

NCT04322123
Cavalcanti AB, N Engl J Med, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with suspected or confirmed COVID-19 (mild-moderate) admitted to 55 centers in Brazil N=667
Some concerns
Details

Full description

Hydroxychloroquine + Azithromycin Standard care
Hydroxychloroquine + Azithromycin Hydroxychloroquine
ChiCTR2000030254
Chen C, medRxiv, 2020
Full text
Commentary
Public/non profit Favipiravir Umifenovir RCT Patients with confirmed COVID-19 (moderate and severe) admitted to 3 centers in China. N=240
High
Details

Full description

NCT04384380
Chen CP , medRxiv, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 11 centers in Taiwan N=33
Some concerns
Details

Full description

NCT04261517
Chen J, J Zhejiang Univ, 2020
Full text
Public/non profit Hydroxychloroquine Standard care RCT Treatment-naive patients with confirmed COVID-19 (moderate) admitted to a single center in China. N=30
High
Details

Full description

NCT04252274
Chen J, Open Forum Infect Dis, 2020
Full text
Commentary
Public/non profit Darunavir/cobicistat Standard care RCT Patients with COVID-19 (moderate) admitted to a single center in China N=30
High
Details

Full description

ChiCTR2000030054
Chen L, medRxiv, 2020
Full text
Commentary
Public Hydroxychloroquine Chloroquine RCT Patients with confirmed COVID-19 (mild, moderate) admitted to a single center in China N=67
High
Details

Full description

Chloroquine Standard care
Hydroxychloroquine Standard care
ChiCTR2000029559
Chen Z, medRxiv, 2020
Full text
Commentary
and Commentary
Public/non profit Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China. N=62
Some concerns
Details

Full description

ChiCTR2000030007
Cheng L, JAMA Intern Med, 2020
Full text
Commentary
Mixed rhG-CSF Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 3 centers in China N=200
Some concerns
Details

Full description

EudraCT number: 2020-001934-37
Corral-Gudino L, medRxiv, 2020
Full text
Commentary
No specific funding Methylprednisolone Standard care RCT “Patients with COVID-19 (severe) admitted to a 5 centers in Spain” N=64
High
Details

Full description

RPCEC00000317
Cruz L, medRxiv, 2020
Full text
Commentary
; Commentary
Mixed CIGB-325 Standard care RCT Patients with confirmed COVID-19 (asymptomatic-severe) admitted to a single center in Cuba N=20
Some concerns
Details

Full description

NCT04349241
Dabbous HM, Research Square, 2020
Full text
Commentary
and Commentary
Private Favipiravir Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to 2 centers in Egypt N=100
Some concerns
Details

Full description

IRCT20100228003449N2
Davoudi-Monfared E, Antimicrob Agents Ch, 2020
Full text
Commentary
Private Interferon beta-1a Standard care RCT Patients with COVID-19 (moderate to critical) admitted to a single center in Iran. N=92
High
Details

Full description

NCT04326790
Deftereos SG, JAMA, 2020
Full text
Commentary
Private Colchicine Standard care RCT Patients with COVID-19 (moderate-severe) admitted to 16 centers in Greece. N=110
Some concerns
Details

Full description

RPCEC00000309
Delgado-Enciso I, Research Square, 2020
Full text
Commentary
Commentary
Mixed Neutral electrolyzed saline Standard care RCT Outpatients with confirmed COVID-19 (ambulatory, mild) treated at home in Mexico. N=84
Some concerns
Details

Full description

NCT02517489
Dequin P-F, JAMA, 2020
Full text
Commentary
Public/non profit Hydrocortisone Placebo RCT Patients with COVID-19 (severe-critical) admitted to 9 centers in France N=149
Low
Details

Full description

jRCTs041190120
Doi Y, Antimicrob Agents Ch, 2020
Full text
Commentary
Mixed Favipiravir Favipiravir RCT Patients with confirmed COVID-19 (asymptomatic-mild-moderate) admitted to multiple centers in Japan N=88
High
Details

Full description

NCT04355936
Duarte M, medRxiv, 2020
Full text
Commentary
Mixed Telmisartan Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in Argentina N=82
Some concerns
Details

Full description

IRCT20200404046947N1
Edalatifard M, Eur Respir J, 2020
Full text
Commentary
Public/non profit Intravenous pulse Methylprednisolone Standard care RCT Patients with confirmed COVID-19 (severe) admitted to two centers in Iran N=68
High
Details

Full description

NCT04366908
Entrenas Castillo M, J Steroid Biochem Mo, 2020
Full text
Commentary
Public/non profit Calcifediol Standard care RCT Patients with confimed COVID-19 (moderate-severe) admitted to a single center in Spain N=76
Some concerns
Details

Full description

RPCEC00000307
Esquivel-Moynelo I, medRxiv, 2020
Full text
Commentary
Public/non profit IFN alpha2b+IFN gamma Interferon alpha2b RCT Patients with confirmed COVID-19 (ambulatory, mild) admitted to a single center in Cuba N=79
High
Details

Full description

IRCT20200406046963N1
Farahani R, Research Square, 2020
Full text
Commentary
Public/non profit IVMP Pulse then Prednisolone Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Iran N=29
High
Details

Full description

ChiCTR2000030262
Fu W, EClinicalMedicine, 2020
Full text
Commentary
Public/non profit Interferon kappa+TFF2 Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China N=80
Some concerns
Details

Full description

NCT04321278
Furtado RHM, Lancet, 2020
Full text
Mixed Hydroxychloroquine + Azithromycin Hydroxychloroquine RCT Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 57 centers in Brazil N=447
Some concerns
Details

Full description

RBR-8969zg
Garcia de Alencar JC, Unpublished Manuscript, 2020, ,
Full text
Commentary
Public/non profit N-acetylcysteine Placebo RCT Patients with COVID-19 (mild-severe) admitted to a single center in Brazil N=140
Some concerns
Details

Full description

NCT04342182
Gharbharan A, medRxiv, 2020
Full text
Commentary
Mixed Convalescent plasma Standard care RCT Patients with COVID-19 (moderate-critical) admitted to 14 centers in the Netherlands N=86
High
Details

Full description

IRCT20200501047259N1
Gharebaghi N, Research Square , 2020
Full text
Public/non profit Intravenous Immunoglobulin Placebo RCT Patients with confirmed COVID-19 (severe) admitted to a single center in Iran N=59
Some concerns
Details

Full description

NCT04292899
Goldman JD, N Engl J Med, 2020
Full text
Commentary
and Commentary
Private Remdesivir 5 Days Remdesivir 10 Days RCT Patients with confirmed COVID-19 (moderate to critical) admitted to 55 centers across 5 countries. N=402
Some concerns
Details

Full description

Forest plots
N/A
Guvenmez O, J Popul Ther Clin Pharmacol, 2020
Full text
Commentary
No specific funding Lincomycin Azithromycin RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in Turkey N=24
Some concerns
Details

Full description

new
NCT04331808
Hermine O, JAMA Intern. Med., 2020
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with COVID-19 (moderate-severe) admitted to nine centers in France N=131
Some concerns
Details

Full description

NCT04381936
Horby P (RECOVERY Trial), N Engl J Med, 2020
Full text
Commentary
Mixed Dexamethasone Standard care RCT Patients with confirmed and unconfirmed COVID-19 (moderate to critical) admitted to 176 hospitals in the United kingdom. N=6425
Some concerns
Details

Full description

Forest plot
(sub group)
NCT04381936
Horby P, Lancet, 2020
Full text
Commentary
Mixed Lopinavir-Ritonavir Standard care RCT Patients with suspected or confirmed COVID-19 (mild-critical) admitted to 163 centers in the UK N=5040
Some concerns
Details

Full description

NCT04381936
Horby P, N Engl J Med, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild-critical) admitted to 176 centers in the UK N=4716
Some concerns
Details

Full description

ChiCTR2000029387
Huang YQ, Front Pharmacol, 2020
Full text
Commentary
Public/non profit Ribavirin+Lopinavir+Ritonavir+Interferon alpha Ribavarin+Interferon alpha RCT Patients with confirmed COVID-19 (moderate) admitted to a single center in China N=101
High
Details

Full description

Lopinavir+Ritonavir+Interferon alpha Ribavarin+Interferon alpha
Ribavirin+Lopinavir+Ritonavir+Interferon alpha Lopinavir+Ritonavir+Interferon alpha
NCT04276688
Hung IF-N, Lancet, 2020
Full text
Commentary
and Commentary
Not reported/unclear Lopinavir + Ritonavir + Ribavirin + Interferon-b-1b Lopinavir + Ritonavir RCT Patients with confirmed COVID-19 (unclear severity) admitted to six centers in Hong-Kong. N=127
Some concerns
Details

Full description

NCT04434248
Ivashchenko AA, Clin Infect Dis, 2020
Full text
Commentary
Mixed Favipiravir 1800/800mg Favipiravir 1600/600mg RCT Patients with confirmed COVID-19 (moderate) admitted to 6 centers in Russia N=60
Some concerns
Details

Full description

Forest plots
Favipiravir 1600/600mg Standard care
Favipiravir 1800/800mg Standard care
RBR-949z6v
Lemos ACB, Thromb Res. , 2020
Full text
Commentary
No specific funding Therapeutic enoxaparin Unfractioned heparin RCT Patients with confirmed COVID-19 (critical) admitted to a single center in Brazil N=20
Some concerns
Details

Full description

ChiCTR2000029638
Li C, Research Square, 2020
Full text
Commentary
Mixed Recombinant super-compound interferon Interferon alpha RCT Patients with COVID-19 (moderate-severe) admitted to 5 centers in China N=96
Some concerns
Details

Full description

ChiCTR2000029757
Li L, JAMA, 2020
Full text
Commentary
Commentary
Public/non profit Convalescent plasma Standard care RCT Patients with COVID-19 (severe to critical) admitted to 7 centers in China. N=103
Some concerns
Details

Full description

NCT04273763
Li T, Clin Transl Sci , 2020
Full text
Commentary
Public/non profit Bromhexine Standard care RCT Patients with confirmed or suspected COVID-19 (mild-moderate) admitted to a single center in China N=18
Some concerns
Details

Full description

RBR-8jyhxh
Lopes MIF, medRxiv, 2020
Full text
Commentary
Public/non profit Colchicine Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Brazil N=38
Some concerns
Details

Full description

ChiCTR2000029544
Lou Y, medRxiv, 2020
Full text
Commentary
Public/non profit Favipiravir Baloxavir marboxil RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in China. N=30
Some concerns
Details

Full description

Baloxavir marboxil Lopinavir + Ritonavir or Darunavir/Cobicistat + Umifenovir + Interferon-a
Favipiravir Lopinavir + Ritonavir or Darunavir/Cobicistat + Umifenovir + Interferon-a
NCT04316377
Lyngbakken MN, Research Square, 2020
Full text
Commentary
No specific funding Hydroxychloroquine Standard care RCT Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Norway N=53 N/A

Full description

RBR-5s2mqg
Mansour E, medRxiv, 2020
Full text
Commentary
Public/non profit Icatibant Standard care RCT Patients with COVID-19 (severe) admitted to a single center in Brazil N=30
Some concerns
Details

Full description

C1 Esterase/Kallikrein Inhibitor Standard care
Icatibant C1 Esterase/Kallikrein Inhibitor
NCT04468646
Mehboob R, medRxiv, 2020
Full text
Commentary
No specific funding Aprepitant+Dexamethasone Dexamethasone RCT Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Pakistan N=41
Some concerns
Details

Full description

NCT04345614
Miller J, Crit Care, 2020
Full text
Commentary
Private Auxora Standard care RCT Patients with confirmed COVID-19 (moderate) admitted to 3 centers in USA N=26
Some concerns
Details

Full description

NCT04304053
Mitjà O, Clin Infect Dis, 2020
Full text
Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild) in an ambulatory setting in Spain N=353
Some concerns
Details

Full description

NCT04434144
Mohiuddin Chowdhury ATM, Research Square, 2020
Full text
Commentary
and Commentary
No specific funding Ivermectin + Doxycycline Hydroxychloroquine + Azithromycin RCT Outpatients with confirmed COVID-19 (asymptomatic, mild) treated at a single center in Bangladesh N=125
High
Details

Full description

IRCT20180725040596N2
Nojomi M, Research Square, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine+Umifenovir Hydroxychloroquine+Lopinavir+Ritonavir RCT Patients with COVID-19 (moderate-severe) admitted to a single center in Iran N=100
Some concerns
Details

Full description

N/A
Podder C, IMC J Med Sci, 2020
Full text
No specific funding Ivermectin Standard care RCT Outpatients with confirmed COVID-19 (mild-moderate) treated at a single center in Bangladesh N=*
High
Details

Full description

NCT04343729
Prado Jeronimo CM, Clin Infect Dis, 2020
Full text
Commentary
Public/non profit Methylprednisolone Placebo RCT Patients with COVID-19 (moderate-critical) admitted to a single center in Brazil N=416
High
Details

Full description

IRCT20100228003449N2
Rahmani H, Int Immunopharmacol, 2020
Full text
Commentary
No specific funding Interferon beta-1b Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran N=80
Some concerns
Details

Full description

ChiCTR2000029853
Ren Z, Adv Sci, 2020
Full text
Commentary
Mixed Azvudine Standard care RCT Patients with COVID-19 (mild-moderate) admitted to a single center in China N=20
Some concerns
Details

Full description

NCT04320615
Rosas I, medRxiv, 2020
Full text
Commentary
Mixed Tocilizumab Placebo RCT Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries N=452
Low
Details

Full description

IRCT20200128046294N2
Sadeghi A, J Antimicrob Chemother, 2020
Full text
Commentary
Mixed Sofosbuvir/daclatasvir Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 4 centers in Iran N=70
Some concerns
Details

Full description

NCT04411667
Sakoulas G, medRxiv, 2020
Full text
Commentary
Private Intravenous Immunoglobulin Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 2 centers in USA. N=34
Some concerns
Details

Full description

IRCT20200418047126N1
Salehzadeh, Research square, 2020
Full text
Commentary
Public/non profit Colchicine Placebo RCT Patients with confirmed COVID-19 (unclear severity) admitted to a single center in Iran N=100
Some concerns
Details

Full description

new
NCT04346355; EudraCT Identifier: 2020-001386-37
Salvarani C, JAMA Intern. Med., 2020
Full text
Commentary
Mixed Tocilizumab Standard care RCT Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy N=126
Some concerns
Details

Full description

ChiCTR2000031494
Shu L, Stem Cell Res Ther, 2020
Full text
Commentary
Public/non profit Human umbilical cord mesenchymal stem cell infusion Standard care RCT “Patients with COVID-19 (mild to severe) admitted to a single center China” N=41
Some concerns
Details

Full description

NCT04308668
Skipper CP, Ann Intern Med, 2020
Full text
Commentary
Private Hydroxychloroquine Placebo RCT Symptomatic, non-hospitalized adults with laboratory-confirmed COVID-19 or probable COVID-19 with high-risk exposure within 4 days of symptom onset. N=491
Some concerns
Details

Full description

NCT04292730
Spinner CD, JAMA, 2020
Full text
Commentary
Private Remdesivir 5 days Standard care RCT Patients with COVID-19 (mild-severe) admitted to 105 centers in the USA, Europe and Asia N=596
Some concerns
Details

Full description

Remdesivir 10 days Standard care
Remdesivir 5 days Remdesivir 10 days
ChiCTR2000029868
Tang W, BMJ, 2020
Full text
Commentary
and Commentary
Mixed Hydroxychloroquine Standard care RCT Patients with COVID-19 (mild, moderate and severe) admitted to 16 centers in China N=150
Some concerns
Details

Full description

NCT04327401
Tomazini, JAMA, 2020
Full text
Commentary
Mixed Dexamethasone Standard care RCT Patients with suspected or confirmed COVID-19 (critical) admitted to 41 centers in Brazil N=299
Some concerns
Details

Full description

NCT04369742
Ulrich RJ, Open Forum Infect Di, 2020
Full text
Commentary
Public/non profit Hydroxychloroquine Placebo RCT Patients with confirmed COVID-19 (mild-severe) admitted to 5 centers in USA N=128
High
Details

Full description

NCT04333420
Vlaar APJ, Lancet , 2020
Full text
30341-6 Commentary
Private IFX-1 Standard care RCT Patients with confirmed COVID-19 (moderate-critical) admitted to three centers N=30
Some concerns
Details

Full description

ChiCTR2000029765
Wang D, SSRN, 2020
Full text
Commentary
Public/non profit Tocilizumab Standard care RCT Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China N=65
High
Details

Full description

ChiCTR2000030058
Wang M, Clin Infect Dis, 2020
Full text
Commentary
Public/non profit Leflunomide + Interferon alpha2a Interferon alpha2a RCT Patients with confirmed COVID-19 (mild) admitted to a single center China N=50
High
Details

Full description

NCT04257656
Wang Y, Lancet, 2020
Full text
Commentary
Mixed Remdesivir Placebo RCT Patients with confirmed COVID-19 (severe) admitted to ten centers in China. N=237
Low
Details

Full description

ChiCTR2000030001
Wu X, Engineering (Beijing) , 2020
Full text
Commentary
Public/non profit Triazavirin Placebo RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 10 centers in China N=52
Some concerns
Details

Full description

ChiCTR2000029431
Yuan, medRxiv, 2020
Full text
Commentary
Public/non profit Tc-MDP Standard care RCT Patients with confirmed COVID-19 (unclear severity) admitted to 2 centers in China N=21 N/A

Full description

NCT04252885
Yueping L, CellPress, 2020
Full text
Commentary
Public/non profit Lopinavir + Ritonavir Standard care RCT Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China. N=86
Some concerns
Details

Full description

Umifenovir Lopinavir + Ritonavir
Umifenovir Standard care
NCT04264533
Zhang J, Research Square, 2020
Full text
Commentary
Public/non profit Vitamin C Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 3 centers in China N=56
Low
Details

Full description

ChiCTR2000030894, NC
Zhao H
Full text
Commentary
Public/non profit Favipiravir Favipiravir+Tocilizumab RCT Patients with confirmed COVID-19 (moderate-critical) admitted to 4 centers in China N=26
Some concerns
Details

Full description

Tocilizumab Favipiravir+Tocilizumab
Favipiravir Tocilizumab
ChiCTR2000029496
Zheng F, Int J Infect Dis, 2020
Full text
Commentary
Public/non profit Novaferon Lopinavir + Ritonavir RCT Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in China. N=89
Some concerns
Details

Full description

Novaferon + Lopinavir + Ritonavir Lopinavir + Ritonavir
Novaferon + Lopinavir + Ritonavir Novaferon
ChiCTR2000029851
Zhong M, medRxiv, 2020
Full text
Commentary
Private a-Lipoic acid Placebo RCT Patients with confirmed COVID-19 (severe-critical) admitted to 1 center in China. N=17
Some concerns
Details

Full description

Kemran S M medRxiv, 2020 trial was not included in our data analysis due to unconvincing randamization that was not clarified by authors quote " Randomization rules were designed by Dr. xxx together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled".